| Document |
Document Title |
|
WO/2000/035868A2 |
Methods for the synthesis of $g(a)-hydroxy-$g(b)-amino acid and amide derivatives and $g(a)-ketoamide derivatives and novel derivatives made by these methods are provided. These methods involve reacting an N-terminally blocked (protected...
|
|
WO/2000/031025A1 |
The invention relates to a method of producing N-alkyl-N'-nitroguanidine. According to said method, an alkyl amine solution is added to a nitroguanidine or nitroguanidine nitrate suspension at temperatures of $m(g) 60 °C and the ammonia...
|
|
WO/2000/021920A1 |
Compounds of the formula (1a), wherein R1 is a group of the formula (2) where R1, R2, A, B, U, V, W, X, Y, Z, k and n have the significance given in the specification, are useful to treat rheumatoid arthritis, psoriasis, multiple scleros...
|
|
WO/1999/054291A1 |
The invention relates to a method for producing a disinfectant based on polyhexamethylene guanidine by the interaction of hexamethylene diamine and guanidine hydrochloride during heating. The hexamethylene diamine and guanidine hydrochlo...
|
|
WO/1999/046316A2 |
The present invention relates to compounds, compositions, and methods which are useful for the prevention and treatment of adverse health, skin, hair, and oral conditions. The compounds, compositions, and methods are also widely applicab...
|
|
WO/1999/043312A1 |
A stable aqueous solution of creatine acid sulfate provides a source of creatine to an animal when taken orally. The aqueous solution of creatine acid sulfate (after neutralization and buffering) has a pH of about 7.2 to about 7.8 and is...
|
|
WO/1999/018053A1 |
According to a first aspect of the invention, a process is disclosed for the preparation of radiolabelled haloaromatic compounds. According to a second aspect of the invention, intermediate precursor insoluble polymer compounds used in t...
|
|
WO/1998/043951A1 |
The invention relates to a novel method for producing n-alkyl-n'-nitroguanidines of formula (I), wherein R stands for C�1?-C�4?-alkyl, alkylamine is neutralized with nitric acid, subsequently reacted with cyanamide and the alkylguani...
|
|
WO/1998/034647A1 |
An arginine silicate-containing complex and its use in the prevention and treatment of atherosclerosis, as a dietary supplement and for promotion of structural integrity of bones and joints. The arginine silicate complex is synthesized b...
|
|
WO/1998/028263A1 |
The invention relates to creatine pyruvates of the general formula (I) (creatine)�x?(pyruvate)�y?(H�2?O)�n?, in which x = 1-100, y = 1-10 and n = 0-10. These creatine pyruvates can be produced by the relatively simple reaction of...
|
|
WO/1998/003518A2 |
Bis-platinum(II) complexes with polymethylene derivatives, the method of making the complexes, and the use of the complexes for the treatment of tumors in mammals, are disclosed. The method of making the polymethylene derivatives, is als...
|
|
WO/1997/045109A1 |
Process for the preparation of 2,2'-(1-methyl-1,2-ethanediylidine)bis[hydrazine carboximidamine] by a) removing impurities from aminoguanidine bicarbonate; b) reacting the aminoguanidine bicarbonate with methylglyoxal dimethylacetal in a...
|
|
WO/1997/035874A1 |
The present invention relates to a novel process for preparing N-methyl-D-phenylalanyl-N-[1-[3-[(aminoiminomethyl)amino]pro
pyl]-3,3-difluoro-2-oxohexyl]-L-prolinamide or a pharmaceutically acceptable salt therof and to a key intermediat...
|
|
WO/1997/033895A1 |
The invention relates to isolated RNA molecules with high affinity for particular amino acids, processes for isolating these, and uses thereof. Via a process which includes various washing and heating steps, one isolates these RNA molecu...
|
|
WO/1997/030972A1 |
The present invention relates to a process for the preparation of NG-monomethyl-L-arginine hydrochloride comprising reaction of a compound of formula (I) or an acid addition salt thereof, wherein L is a leaving group; with L-ornithine or...
|
|
WO/1997/015280A1 |
The use of at least one NO synthase inhibitor as the active principle in a cosmetic composition for treating and/or preventing sensitive skin is disclosed. The use of at least one NO synthase inhibitor for preparing a pharmaceutical and ...
|
|
WO/1996/024579A1 |
Compounds selected from the group consisting of (i) products of formula (I), wherein R is a hydrogen atom, an OH group, an OCH3 group or a CH2OH group, *C, when R is not a hydrogen atom, is an asymmetrical carbon atom having configuratio...
|
|
WO/1996/021642A1 |
The process comprises a first step of esterification of an aminoacid and is characterized by a second step of condensation of a fatty acid chloride with an esterified amino acid derivative. It relates to the synthesis of surfactant compo...
|
|
WO/1996/008469A1 |
The present invention is the novel synthesis of sterically hindered penta-substituted guanidines by a process in which (1a) an isocyanate is reacted first with a di-substituted amine or (1b) a urea is reacted with two moles of a mono-sub...
|
|
WO/1995/022398A1 |
A process for recovering guanidine salts from diluted and contaminated aqueous solutions is described, wherein the corresponding aqueous solution (diluate) is subjected to electrodialysis and the guanidine salt is concentrated on the con...
|
|
WO/1995/000474A1 |
Methods of making unnatural amino acids which can be incorporated into peptides which either inhibit or promote the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads which method comprise...
|
|
WO/1994/029269A1 |
A process for the production of guanidino protected omega-aminoalkyl guanidines comprising reacting a diamine selectively at one amino group with an alkoxycarbonyl or aralkoxycarbonyl protected electrophilic guanylation reagent. The proc...
|
|
WO/1994/026701A1 |
A process is disclosed for the preparation of N_G-monoalkyl-L_-arginine and related compounds and salts thereof, for example N_G-monomethyl-L-arginine by reacting N-alkylaminoiminomethane sulphonic acid of formula (II) with an amino acid...
|
|
WO/1994/022807A1 |
A compound having formula (I) or a pharmaceutically acceptable salt thereof, wherein X and Z each independently are NH or CH2, at least one of X and Z being NH; Y is O, S, NCN, or NH; B, D, E and F each independently are C or N, at least...
|
|
WO/1994/002453A1 |
(S)-N5-[Imino(methylamino)methyl]ornithine hydrochloride, pharmaceutical compositions containing it, its us in medicine and its preparation is described.
|
|
WO/1993/019042A1 |
A process for the preparation of a substituted guanidine by reacting a substituted cyanamide with ammonia or a substituted amine in the presence of a Lewis acid catalyst. Also disclosed is a process for the preparation of a tri-substitut...
|
|
WO/1993/017017A1 |
The present invention is concerned with vasoconstrictive [(benzodioxan, benzofuran or benzopyran)alkylamino]alkyl substituted guanidines having formula (I), the pharmaceutically acceptable acid addition salts thereof, and the stereochemi...
|
|
WO/1991/004023A1 |
Pharmaceutically pure physiologically active NG-aminoarginine (i.e., the L or D,L form) or pharmaceutically acceptable salt thereof is administered in a nitric oxide synthesis inhibiting amount to a subject in need of such inhibition (e....
|
|
WO/1990/013536A1 |
Antimicrobial bis-(pyrrolidonyl alkylene) biguanides having the formula: A-Z-A where A is: (I); X is C2-C4 alkylene; and Z is a bivalent bridging group, and acid addition salts thereof, are provided herein.
|
|
WO/1986/000893A1 |
Novel amidine compounds represented by formula (I) (wherein R1 and R2 each represents hydrogen, a straight or branched chain alkyl group containing 1 to 6 carbon atoms, R3 represents a straight or branched chain alkyl group containing 1 ...
|
|
JP2024071390A |
The present invention provides a method for producing metformin that does not cause the above-mentioned drawbacks of conventional production methods. The present invention relates to an improved process for the preparation of metformin h...
|
|
JP7464280B2 |
Provided are an environmentally-friendly high-efficiency method of manufacturing an ester compound based on an esterification reaction using a salt ion-exchange method and an ester compound manufactured thereby. In the conventional ester...
|
|
JP7447005B2 |
The present invention relates to an improved process for the preparation of metformin hydrochloride, an important drug in the first line treatment of Type II Diabetes.
|
|
JP2024504532A |
The present invention relates to a novel co-crystal, a pharmaceutical composition containing the same, and a method for producing the same, and utilizes the co-crystal of the present invention to effectively prevent and/or prevent cancer...
|
|
JP7403624B2 |
The present invention relates to a novel crystal modification of N-(aminoiminomethyl)-2-aminoacetic acid, crystal mixtures, and a process for preparing said crystal modification and said crystal mixtures.
|
|
JP7399996B2 |
The present disclosure provides purified forms of iobenguane and preparations of a precursor to iobenguane, such as a polymer, the polymer comprising a monomer of formula (I) or a pharmaceutically acceptable salt thereof, the preparation...
|
|
JP7386383B2 |
The invention concerns a compound according to following formulawherein R1 is a halogen residue.
|
|
JP2023539760A |
The present invention is a method for producing guanidinoacetic acid by reacting cyanamide with glycine in an aqueous reaction mixture in the presence of a base, the ammonia content in the reaction mixture being controlled to 20 g/L or l...
|
|
JP2023539759A |
The present invention combines cyanamide with an excess molar amount of glycine in an aqueous reaction mixture in the presence of a base, avoiding high molar amounts of base or acid for pH control while preserving reaction selectivity an...
|
|
JP7274000B2 |
The present invention relates to a method for producing peramivir trihydrate, which is an inhibitor of neuraminidase infection, as an anti-influenza agent. According to the production method of the present invention, peramivir trihydrate...
|
|
JP7264999B2 |
The present disclosure discloses salts formed by 2-(1-acyloxy-n-pentyl)benzoic acid and basic amino acid or aminoguanidine, a preparation method thereof, pharmaceutical preparations containing these salts, and application thereof in prep...
|
|
JP2023514505A |
The present disclosure provides basic amino acid salts of polyunsaturated fatty acids (PUFAs) and methods for their preparation comprising combining one or more PUFAs in acid form and basic amino acids in a first organic solvent and wate...
|
|
JP2022540331A |
The present invention relates to novel crystalline modifications of N(aminoiminomethyl)-2-aminoacetic acid, crystalline mixtures and processes for preparing said crystalline modifications and said crystalline mixtures. [Selection figure]...
|
|
JP2022109243A |
To provide various co-crystal nafamostat mesylate and their manufacturing methods.A co-crystal of nafamostat mesylate, characterized in that the nafamostat mesylate and a pharmaceutically acceptable co-former consist of a co-crystal phas...
|
|
JP7005071B1 |
To provide a bioavailability of a metformin base, which is weaker in hygroscopicity, has better solubility in water, can delay the intrinsic dissolution rate of metformin, is more stable and easy to store, as compared with a conventional...
|
|
JP6983070B2 |
Disclosed are metal organic framework materials (MOFs), comprising an extra-framework NO releasing compound within the internal pores and/or channels of the MOF, the NO-releasing compounds and their preparation and uses. The MOFs and NO-...
|
|
JP6875826B2 |
To provide a manufacturing method capable of manufacturing guanidine oxalate, especially amino guanidine oxalate easily at high yield.There is provided a manufacturing method of guanidine oxalate having a mixing process for mixing a gran...
|
|
JP6793184B2 |
Therein, R1 and R2 are in each case hydrogen, halogen and alkyl, and R3 and R4 are in each case hydrogen, alkyl, cycloalkyl and aryl.
|
|
JP2020180147A |
To provide (2S,4R)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalyl
amino)-2-hydroxymethyl-2-methylpentanoic acid as a neprilysin inhibitor, and processes for preparing the same.The present invention provides a compound having a stru...
|
|
JP6748188B2 |
The present invention relates to a process for the preparation of the compound N-(3,5-dimethylphenyl)-N'-(2-trifluoromethylphenyl) guanidine of formula (I) which comprises reacting a salt of a compound of formula (II) or a mixture of the...
|
